Table 1. Clinical and Laboratory Characteristics of Included Patients.

	Fibrosis Group (n = 14)	Non-Fibrosis Group (n = 18)	P
Clinical characteristic
Age (year)	54.0 (49.0–65.3)	37.0 (30.5–52.5)	0.008
Male: female ratio	12:2	10:8	0.124
Comorbidity
Diabetes	1 (7.1)	1 (5.6)	> 0.050
Hypertension	4 (28.6)	0 (0)	0.028
Cardiac disease	1 (7.1)	1 (5.6)	> 0.050
Chronic obstructive pulmonary disease	1 (7.1)	0 (0)	0.437
Signs and symptoms
Fever	14 (100)	13 (72.2)	0.052
Dyspnea	6 (42.9)	1 (5.6)	0.027
Cough	6 (42.9)	9 (50.0)	0.735
Fatigue	7 (50.0)	7 (38.9)	0.721
Muscle ache	5 (35.7)	3 (16.7)	0.252
Diarrhea	0 (0)	2 (11.1)	0.492
Respiratory rate (breaths per min)	20.0 (18.8–27.8)	18.5 (18.0–20.0)	0.026
Laboratory examinations
White blood cell count (x109/L)	3.8 (2.8–5.4)	4.0 (2.9–4.4)	0.687
Lymphocyte count (x109/L)	0.6 (0.4–0.9)	1.1 (0.8–1.3)	0.003
Lactic dehydrogenase (U/L)	289.0 (179.0–428.5)	180.0 (148.5–191.0)	0.014
Creatine kinase (U/L)	112.0 (68.0–203.5)	62.0 (51.5–114.5)	0.031
C-reactive protein (mg/L)	53.4 (29.6–111.2)	10.0 (5.2–23.6)	0.002
Alanine transaminase (U/L)	52.0 (31.0–142.0)	23.5 (12.0–39.0)	0.021
Creatinine (μmol/L)	81.2 (73.1–94.8)	69.1 (61.5–80.3)	0.029
Interleukin-6 (pg/mL)	79.7 (10.5–98.3)	11.2 (4.4–19.2)	0.040
Treatment
Pulsed steroid therapy	11 (78.6)	10 (55.6)	0.266
Days of pulsed steroid therapy	11.0 (8.0–13.0)	5.0 (3.0–6.3)	< 0.001
Antiviral therapy	14 (100)	18 (100)	-
Days of antiviral therapy	12.0 (9.5–14.8)	6.5 (5.0–12.0)	0.012
Others
Length of hospital stay (day)	19.5 (11.5–21.8)	10.0 (6.0–15.3)	0.001
Intensive care unit admission	5 (35.7)	0 (0)	0.010
Days from illness onset to initial CT scan	5.5 (3.0–7.3)	2.5 (1.0–5.3)	0.039
Days from illness onset to worst CT scan	11.0 (7.0–15.0)	9.5 (6.5–11.0)	0.042
Days after discharge to latest follow-up CT scan	9.0 (7.0–11.0)	9.0 (7.8–11.3)	-

Data are median (interquartile range) or n (%).